Information Provided By: 
Fly News Breaks for November 6, 2019
RDUS
Nov 6, 2019 | 08:04 EDT
SVB Leerink analyst Geoffrey Porges lowered his price target for Radius Health to $35 from $49 following the company's quarterly results, saying that while the Tymlos market share gains remain on track with management guidance, the incremental value potential for other late stage development programs is fading with newly announced delays in the timing of the patch pivotal trial, and a formal decision to pivot away from oncology. Porges keeps an Outperform rating on the shares.
News For RDUS From the Last 2 Days
There are no results for your query RDUS
